PTCT - PTC Therapeutics Inc Stock Price, Fair Value and News

34.08USD+0.51 (+1.52%)Market Closed

Market Summary

USD34.08+0.51

Market Closed

1.52%

PTCT Stock Price

View Fullscreen

PTCT RSI Chart

PTCT Valuation

Market Cap

2.6B

Price/Earnings (Trailing)

-4.51

Price/Sales (Trailing)

2.82

EV/EBITDA

-6.35

Price/Free Cashflow

-30.42

PTCT Price/Sales (Trailing)

PTCT Profitability

EBT Margin

-69.63%

Return on Equity

64.8%

Return on Assets

-32.37%

Free Cashflow Yield

-3.29%

PTCT Fundamentals

PTCT Revenue

Revenue (TTM)

927.6M

Rev. Growth (Yr)

-4.66%

Rev. Growth (Qtr)

-31.57%

PTCT Earnings

Earnings (TTM)

-579.2M

Earnings Growth (Yr)

34.1%

Earnings Growth (Qtr)

41.22%

Breaking Down PTCT Revenue

Last 7 days

2.3%

Last 30 days

-4.5%

Last 90 days

17.5%

Trailing 12 Months

-15.9%

How does PTCT drawdown profile look like?

PTCT Financial Health

Current Ratio

2.03

Debt/Equity

-0.32

Debt/Cashflow

-0.2

PTCT Investor Care

Shares Dilution (1Y)

3.38%

Diluted EPS (TTM)

-7.68

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	927.6M	0	0	0
2023	770.4M	818.7M	798.2M	937.8M
2022	569.4M	618.2M	696.6M	698.8M
2021	430.4M	471.9M	492.2M	538.6M
2020	321.7M	311.4M	358.4M	380.8M
2019	261.8M	278.5M	296.4M	307.0M
2018	203.7M	224.5M	236.3M	264.2M
2017	90.3M	122.5M	141.3M	174.1M
2016	48.2M	57.0M	70.2M	82.7M
2015	23.5M	28.6M	36.7M	36.8M
2014	36.8M	31.6M	17.0M	25.2M
2013	28.6M	27.8M	36.9M	34.7M
2012	113.1M	115.9M	36.7M	33.9M
2011	0	0	0	105.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About PTC Therapeutics Inc

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease; bio-e platform, such as vatiquinone and utreloxastat; metabolic platform comprising sepiapterin; gene therapy platform, including an asset targeting Friedreich ataxia; oncology platform, such as Unesbulin; and other multi-platform. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.

CEO	Dr. Matthew B. Klein F.A.C.S., FACS, M.D., M.S., MS
WEBSITE	ptcbio.com
INDUSTRY	Biotechnology
EMPLOYEES	1402

PTC Therapeutics Inc Frequently Asked Questions

What is the ticker symbol for PTC Therapeutics Inc? What does PTCT stand for in stocks?

PTCT is the stock ticker symbol of PTC Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of PTC Therapeutics Inc (PTCT)?

As of Thu Jul 25 2024, market cap of PTC Therapeutics Inc is 2.57 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PTCT stock?

You can check PTCT's fair value in chart for subscribers.

Is PTC Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether PTCT is over valued or under valued. Whether PTC Therapeutics Inc is cheap or expensive depends on the assumptions which impact PTC Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PTCT.

What is PTC Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, PTCT's PE ratio (Price to Earnings) is -4.45 and Price to Sales (PS) ratio is 2.78. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PTCT PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on PTC Therapeutics Inc's stock?

In the past 10 years, PTC Therapeutics Inc has provided 0.021 (multiply by 100 for percentage) rate of return.